Scientists investigated the therapeutic potential of p53-expressing telomerase-specific oncolytic adenovirus OBP-702 to induce immunogenic cell death and antitumor immune responses in human pancreatic ductal adenocarcinoma cells with different p53 status.
[Molecular Therapy Oncolytics]
